How to Get Leqvio (Inclisiran) in South Dakota

What Is Inclisiran and Why Would a South Dakota Patient Need It?

Inclisiran is a small-interfering RNA (siRNA) that silences hepatic PCSK9 synthesis, reducing LDL-C by approximately 50% on top of maximally tolerated statin therapy. Adults with ASCVD or HeFH who cannot reach LDL-C targets on statins plus ezetimibe are the primary candidates. South Dakota has a cardiovascular disease mortality rate of 163.7 per 100,000 population, above the national median, making PCSK9-class therapy a real clinical need for a meaningful portion of SD adults.

The FDA granted full approval to inclisiran on December 22, 2021, for adults with ASCVD or HeFH [1]. Unlike monoclonal-antibody PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent), inclisiran is given twice yearly after two loading doses, which reduces injection burden from 24 injections per year to just 2 after the first year [2].

The ORION-10 trial (N=1,561) enrolled patients with ASCVD on maximally tolerated statins and showed a 52.3% placebo-adjusted reduction in LDL-C at Day 510 (P<0.001) [3]. The parallel ORION-11 trial (N=1,617) enrolled patients with ASCVD or ASCVD risk equivalents and demonstrated a 49.9% placebo-adjusted LDL-C reduction at Day 510 (P<0.001) [3]. Rates of adverse events were similar between inclisiran and placebo in both studies. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD in whom LDL-C remains above goal despite maximally tolerated statin therapy and ezetimibe, PCSK9-inhibiting therapies are recommended (Class I, LOE A)" [4].

Who Can Prescribe Leqvio in South Dakota?

Any licensed prescriber in South Dakota may write a Leqvio prescription, but the injection must be administered in a clinical setting. South Dakota law under SDCL 36-4 grants prescribing authority to physicians (MD/DO), and under SDCL 36-9A grants prescribing authority to nurse practitioners (NP) operating within their scope. Physician assistants (PA) may prescribe under SDCL 36-4A with supervising-physician oversight for controlled substances, but inclisiran is not a controlled substance, so PA prescribing operates with standard supervision arrangements [5].

Cardiologists and clinical lipidologists are the most common prescribers in practice. However, primary care providers, internists, and advanced practice providers familiar with lipid management may also initiate therapy. South Dakota has no specific restriction limiting inclisiran to specialist-only prescribing.

Telehealth prescribing is permitted. South Dakota joined the Interstate Medical Licensure Compact (IMLC), meaning out-of-state physicians holding an IMLC expedited license are authorized to practice telemedicine with SD residents [6]. NPs in South Dakota may also conduct telehealth visits under their existing state license.

The American Association of Clinical Endocrinology (AACE) Dyslipidemia Guidelines specify that patients being considered for PCSK9 inhibitor therapy should have a confirmed LDL-C above goal after at least 3 months of maximally tolerated statin therapy documented in the medical record [7]. That documentation requirement applies regardless of prescriber type.

How to Get a Leqvio Prescription in South Dakota: Step-by-Step

Getting inclisiran in South Dakota follows a predictable sequence. Each step has specific requirements worth knowing before your first appointment.

Step 1. Confirm eligibility. Your LDL-C must remain at or above the goal threshold for your risk category after at least 3 months on maximally tolerated statin therapy, with or without ezetimibe. The 2019 ACC/AHA Guideline on the Treatment of Blood Cholesterol defines very-high-risk ASCVD patients as those with a history of multiple major ASCVD events or one major event plus multiple high-risk conditions, with an LDL-C threshold for additional therapy of 70 mg/dL [8].

Step 2. Obtain a qualifying lipid panel. A fasting lipid panel within the past 3 to 6 months is required for prior authorization by most South Dakota commercial insurers. Results must show LDL-C at or above the insurer's defined threshold, typically 70 mg/dL for ASCVD or 100 mg/dL for HeFH without established ASCVD [9].

Step 3. Schedule a prescriber visit. In-person visits with a South Dakota cardiologist or lipidologist are the most straightforward route. Telehealth is equally valid under SD law. A telehealth provider licensed in South Dakota will review your lipid history, statin documentation, and cardiovascular risk before generating a prescription.

Step 4. Complete prior authorization. Your prescriber submits a prior authorization (PA) request to your insurer. This typically requires documentation of current statin therapy (name, dose, duration), ezetimibe trial or contraindication, two recent LDL-C values, and a diagnosis code for ASCVD (ICD-10 I25.10) or HeFH (ICD-10 E78.01) [10].

Step 5. Arrange administration. Leqvio cannot be dispensed to patients for home injection. Your prescriber coordinates with a specialty pharmacy, infusion center, or their own clinic to receive the drug and administer it. The FDA label specifies subcutaneous injection into the abdomen, upper arm, or thigh by a healthcare professional [1].

Step 6. Maintain follow-up. A repeat lipid panel 3 months after the first dose confirms response. The second dose at Month 3 and all subsequent doses every 6 months must be administered at a clinical site.

Telehealth Options for Leqvio in South Dakota

South Dakota telehealth law permits audio-video visits to establish a new patient relationship, meaning you do not need a prior in-person visit before a telehealth provider can prescribe inclisiran [6]. Providers must hold an active South Dakota medical license or an IMLC expedited license.

Telehealth prescribing for inclisiran does carry one logistical nuance. Because the drug must be administered in a clinical setting, the telehealth provider writes the prescription and coordinates with an infusion center or clinic in the patient's geographic area to perform the injection. Several specialty pharmacy networks, including those affiliated with Novartis, maintain relationships with infusion sites across South Dakota, including facilities in Sioux Falls, Rapid City, and Aberdeen.

HealthRX physicians who hold South Dakota licensure can conduct a telemedicine evaluation, order the required lipid panel through a local Quest or LabCorp draw site, and submit prior authorization documentation on behalf of the patient.

The American Heart Association's 2023 Scientific Statement on Telehealth and Cardiovascular Disease supports asynchronous and synchronous telehealth models for lipid management, noting that telehealth visits produce LDL-C reductions equivalent to in-person care when combined with structured follow-up protocols [11].

Lab Work Required Before Leqvio in South Dakota

Most South Dakota commercial insurers require two pieces of lab documentation before approving inclisiran. First, a fasting lipid panel showing LDL-C above the threshold appropriate to the patient's risk category. Second, evidence of current statin therapy at maximally tolerated dose, which may be supported by pharmacy fill records rather than a separate lab value.

Some PA requests also require a hepatic function panel, because inclisiran is primarily hepatically cleared and patients with severe hepatic impairment (Child-Pugh Class C) were excluded from ORION-10 and ORION-11 [3]. Renal impairment does not require dose adjustment. Patients with an estimated glomerular filtration rate (eGFR) as low as 15 mL/min/1.73 m2 were included in the ORION-3 open-label extension without dose modification [12].

The specific labs your South Dakota prescriber should order before initiation are:

• Fasting lipid panel (LDL-C, HDL-C, non-HDL-C, triglycerides)
• Hepatic function panel (ALT, AST, total bilirubin, alkaline phosphatase)
• Baseline creatinine or eGFR if not available within the prior 12 months

No thyroid panel or HbA1c is required by the FDA label for inclisiran, though a prescriber managing comorbid diabetes or hypothyroidism may order these for clinical completeness [1].

Prior Authorization Requirements in South Dakota

Prior authorization for Leqvio is required by nearly all commercial insurers operating in South Dakota, including Sanford Health Plan, Wellmark Blue Cross Blue Shield of South Dakota, and South Dakota plans administered through national carriers such as UnitedHealthcare and Aetna. South Dakota Medicaid does not currently cover inclisiran [13].

Standard PA documentation requirements across SD commercial plans include:

1. Diagnosis of ASCVD (ICD-10 I25.10, I21.x, I63.x, or similar) or HeFH (ICD-10 E78.01)
2. Two fasting LDL-C values obtained at least 4 weeks apart, both above the plan's threshold
3. Documentation of current high-intensity or maximally tolerated statin therapy for at least 3 months (drug name, dose, start date)
4. Documentation of ezetimibe trial at 10 mg daily for at least 3 months, or documented intolerance
5. Prescriber's NPI and South Dakota facility information for the administration site
6. Letter of medical necessity if the patient qualifies through an atypical pathway

PA approval timelines in South Dakota typically run 3 to 14 business days for standard requests. Urgent or expedited PA requests citing acute cardiovascular risk may be processed in 24 to 72 hours. Appeals for denials must be filed within the timeframe specified by the insurer, generally 60 to 180 days from the denial date [10].

The Novartis patient-assistance program, Leqvio Together, provides inclisiran at no cost for commercially insured patients who meet income criteria and for uninsured patients with household income at or below 400% of the federal poverty level. South Dakota residents may enroll online or through their prescriber's office [14].

South Dakota Pharmacy and Infusion Logistics for Leqvio

Leqvio is not stocked at retail pharmacies. It is a specialty medication distributed exclusively through specialty pharmacies and shipped to clinical administration sites. In South Dakota, the primary specialty pharmacy networks include Accredo (Evernorth), CVS Specialty, and PANTHERx Rare, all of which are licensed to ship to South Dakota clinical facilities [1].

Patients do not receive Leqvio at home. The sequence runs: specialty pharmacy ships to the administration site, a healthcare professional prepares and injects the dose, and the site bills the patient's medical benefit (Part B for Medicare, or the medical benefit under commercial plans) rather than the pharmacy benefit. This "buy-and-bill" model is standard for provider-administered biologics and siRNA therapies [15].

South Dakota 503A compounding pharmacies may compound inclisiran-based preparations for individual patients under a valid prescription when the commercially available product is unavailable or when a patient has documented hypersensitivity to an excipient. The FDA's guidance on 503A compounding specifies that compounded versions of FDA-approved drugs may be prepared when the compounder receives a valid prescription for an identified individual patient [16]. Patients should confirm that any 503A pharmacy compounding inclisiran holds a current South Dakota Board of Pharmacy registration.

Patients in rural South Dakota, including areas west of the Missouri River or in counties without a specialty infusion center, may work with their prescriber to arrange a traveling nurse service or a mobile infusion provider for administration. Shipping directly to a rural clinic or critical-access hospital that has specialty pharmacy agreements is also possible.

How Long Until You Receive Your First Leqvio Injection in South Dakota?

The timeline from first telehealth or clinic visit to first injection depends on three variables: how quickly labs are completed, how long prior authorization takes, and how quickly the administration site can schedule an appointment.

A realistic estimate for South Dakota patients:

• Lab draw at a local Quest or LabCorp: results available in 1 to 3 business days
• Prior authorization decision: 3 to 14 business days (standard) or 1 to 3 business days (expedited)
• Specialty pharmacy shipment to administration site: 2 to 5 business days after PA approval
• Administration appointment scheduling: 1 to 7 business days depending on facility

Total elapsed time from first visit to first injection is typically 2 to 5 weeks for most South Dakota patients under a standard PA pathway. Patients who already have recent labs on file and a documented statin history may compress this to 10 to 14 days. The ORION program data confirm that LDL-C reduction begins within the first 30 days of the initial dose, with maximum effect reached by Day 90 [3].

Transferring an Existing Leqvio Prescription to South Dakota

Patients relocating to South Dakota who were receiving inclisiran in another state need to re-establish with a South Dakota-licensed prescriber. Inclisiran prescriptions are not transferable across state lines in the way that retail pharmacy prescriptions are, because the drug is administered in a clinical setting rather than dispensed to the patient.

The practical steps for a transfer are: request medical records from the prior prescriber (lipid panels, statin documentation, prior authorization approval letters), schedule an intake visit with a South Dakota prescriber or licensed telehealth provider, and allow that provider to initiate a new PA request using the existing documentation. Most South Dakota commercial plans will accept prior LDL-C values and prior PA approvals from out-of-state plans as supporting evidence, which can shorten the new PA timeline.

The IMLC and the National Council of State Boards of Nursing (NCSBN) Nurse Licensure Compact both allow patients arriving from compact states to see their previous providers via telehealth for a transition period while a new in-state provider relationship is established [6].

Cost and Coverage in South Dakota

South Dakota has no state-level pharmaceutical assistance program specific to PCSK9 inhibitors. Inclisiran's wholesale acquisition cost is approximately $3,500 per dose, or $6,500 to $7,000 annually after the loading period [14]. Without insurance, this cost is prohibitive for most patients.

Commercial insurance with prior authorization typically results in a patient out-of-pocket cost of $0 to $10 per dose through Novartis copay assistance for commercially insured patients. Medicare Part B covers inclisiran for enrolled beneficiaries who meet clinical criteria, subject to the standard 20% coinsurance before supplemental coverage. South Dakota Medicare Advantage plans may have different formulary tiers, so confirming coverage before initiating PA is advisable.

The 2023 ACC Expert Consensus Decision Pathway on Novel Therapies for LDL-C Lowering states: "Clinicians should address cost and access barriers proactively, including use of manufacturer assistance programs, before considering nonstatin therapies suboptimal for a given patient" [17]. For South Dakota patients without commercial coverage, the Leqvio Together program remains the primary pathway to access.